Mikhail Blagosklonny and his Research on Cancer and Aging

Education and work background
Mikhail Blagosklonny is an expert who studies aging and cancer. Currently, Mikhail Blagosklonny is a professor at Roswell Park Cancer Institute where he teaches oncology. Mikhail trained at the First Pavlov State Medical University of St. Petersburg where he attained his M.D. and Ph.D. in cardiology and experimental medicine. In 2002, New York Medical College hired him as an Associate Professor of Medicine. Later, he joined Ordway Research Institute as the senior scientist. He remained at Ordway until in 2009 when he was hired by Roswell Park Cancer Institute as the professor of oncology.

Mikhail Blagosklonny is interested in several studies such as cancer whereby he research on targeted cancer therapies that keep normal cells from damage by chemotherapy and radioactive rays, the mechanism of aging (biogerontology), as well as anti-aging treatments. Other research interests include cellular and molecular biology and clinical investigations. His research includes cell cycle, anti-cancer therapeutics, cellular senescence, and signal transduction.

His passion led him to further the study of signal transduction pathways that leads from cancer to aging. In the process, he revealed potential targets that slow down the aging process and age-related illnesses.

Read more: Rejuvenating immunity: “anti-aging drug today” eight years later

Hypothesis on the possible role of TOR
Driven by his interest in cancer and aging, Mikhail Blagosklonny postulated a theory about the probable role of TOR in cancer as well as aging. He proposed that rapamycin, a prominent cancer drug can be a treatment for extending a person’s life.

Editorial works
Mikhail is a chief author in oncotarget, cell cycle, and aging. Additionally, he is a subordinate editor of cancer therapy and biology. Mikhail Blagosklonny is a founding editor and chief editor of cancer research, International Journal of Cancer, Cell death and differentiation, American Journal of Pathology, and Autophagy. Oncotarget is a weekly medical journal that covers oncology research. This journal was launched in 2010. Andrei V. Gudkov and Mikhail Blagosklonny from Roswell Park Cancer Center are the chief editors. Mikhail has written more than 170 research articles.

Roswell Park Cancer Institute
Mikhail was appointed to join the institution on April 15, 2009. The staff was enthusiastic about his appointment. At Roswell, the experts share ideas and possible approaches to curb cancer. Some ideas include Tissue-specific therapy of cancer and how cancer can be prevented by slowing down aging. The institution harnesses the modern imaging technology such as optical scanners, PET, MRI, ultrasound, and CT to visualize the growth of abnormal tumors in lab animals. Mikhail extensive knowledge on cancer and aging will be useful to the center.

Find works by Mikhail Blagosklonny on NCBI – PubMed.com
Read more about Mikhail Blagosklonny on T and F Online